Emerging data suggest Retatrutide , a dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could represent a promising development for weight loss . Early clinical investigations have indicated impressive decreases in body mass , possibly exceeding existing obesity therapies . However , more study is needed to thor